Potential Combination Therapy Approaches with Ruxolitinib in Myelofibrosis
April 26th 2023A review of recent trial data evaluating combination therapy approaches with ruxolitinib in myelofibrosis, including the rationale and potential clinical benefits associated with the use of these emerging strategies.
Read More
Abemaciclib/Fulvestrant Boosts PFS in HR+/HER2– Breast Cancer Post–CDK4/6i Progression
Inavolisib Plus Palbociclib/Fulvestrant Bolsters PFS in HR+/HER2–, PIK3CA-Mutant Breast Cancer
Dr Cho on Amivantamab Plus Lazertinib in Atypical EGFR-Mutated NSCLC
Dr Freedland on Treatment Suspension and HRQoL During the EMBARK Trial in nmHSPC
2 Commerce Drive
Cranbury, NJ 08512